Alzheimer's Trial Results Expected in November
The XanaMIA study investigates if a new drug can slow disease progression, with findings expected by mid-November 2026.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Do you believe current medical research is making sufficient progress in treating Alzheimer's disease?
Actinogen Medical has locked the trial database for its XanaMIA study, moving toward the final analysis of its Alzheimer's drug candidate Xanamem. The trial, which concludes after 36 weeks, will provide initial data on the treatment's efficacy for participants in Australia and the US.
Why it matters
This trial investigates whether lowering brain cortisol levels can slow Alzheimer's disease progression, a potential new therapeutic avenue. The upcoming results are a key step for those following new treatments targeting specific biomarkers like pTau181.
This Phase 2 study enrolled 247 patients across Australia and the US over 36 weeks, using blood tests to identify elevated pTau181 levels for inclusion. Researchers are currently analyzing the data, and clinical efficacy results remain unknown until the report in mid-November 2026.
The players
Actinogen Medical
An Australian biotechnology company focused on developing therapies for neurodegenerative and psychiatric conditions including Alzheimer's and depression.
The details
The experimental drug Xanamem is designed to modulate cortisol levels within the brain to address neurodegenerative changes. By locking the database, the researchers have finalized the dataset to ensure the integrity of the upcoming statistical analysis. Participants were selected based on elevated pTau181 levels, a biological marker often associated with Alzheimer's disease pathology.
Timeline
The XanaCIDD depression trial was conducted in 2024.
The XanaMIA-OLE extension trial commenced in March 2026.
The company finalized the XanaMIA database lock in October 2026.
Trial results are expected to be released in mid-November 2026.
Health Landscape
This study contributes to the broader research effort regarding cortisol-modulating therapies for neurodegeneration. It represents a shift from traditional amyloid-focused approaches by targeting the role of cortisol in brain health.
This development is part of an ongoing clinical trial process and does not represent an available treatment for Alzheimer's disease today. For those interested in how these research advancements might influence care, the trial's biomarker-based selection is a topic worth discussing with your doctor.
The takeaway
The XanaMIA trial is moving toward a data release that could provide insight into cortisol-targeted therapy for Alzheimer's disease. Those tracking clinical progress should watch for the anticipated mid-November 2026 report to understand the future of this research area.
What happens next
Actinogen Medical expects to release the final results of the XanaMIA clinical trial in mid-November 2026.
Further reading
For more on current research and treatment pathways, visit our Alzheimer’s section.
Live Poll
Do you believe current medical research is making sufficient progress in treating Alzheimer's disease?
